Dimensional Fund Advisors
XENE icon

Dimensional Fund Advisors’s Xenon Pharmaceuticals XENE Stock Holding History

Dimensional Fund Advisors’s Portfolio XENE Stock Details XENE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.21M Buy
+36,595
New +$2.03M ﹤0.01% 2723
2026
Q1 		– Sell
-452,147
Closed -$20.3M – 3304
2025
Q4 		$20.3M Sell
452,147
-1,876
-0.4% -$78.8K ﹤0.01% 1957
2025
Q3 		$18.2M Buy
454,023
+74,035
+19% +$2.61M ﹤0.01% 2032
2025
Q2 		$11.9M Buy
379,988
+165,128
+77% +$5.39M ﹤0.01% 2211
2025
Q1 		$7.21M Sell
214,860
-45,110
-17% -$1.71M ﹤0.01% 2377
2024
Q4 		$10.2M Sell
259,970
-39,895
-13% -$1.65M ﹤0.01% 2299
2024
Q3 		$11.8M Sell
299,865
-136,595
-31% -$5.51M ﹤0.01% 2232
2024
Q2 		$17M Buy
436,460
+26,253
+6% +$1.05M ﹤0.01% 2039
2024
Q1 		$17.7M Buy
410,207
+7,539
+2% +$347K ﹤0.01% 2053
2023
Q4 		$18.5M Sell
402,668
-24,457
-6% -$864K 0.01% 2024
2023
Q3 		$14.6M Buy
427,125
+165,018
+63% +$6.17M ﹤0.01% 2080
2023
Q2 		$10.1M Buy
262,107
+196,841
+302% +$7.82M ﹤0.01% 2253
2023
Q1 		$2.34M Buy
+65,266
New +$2.41M ﹤0.01% 2710
2022
Q3 		$12.3M Buy
342,031
+167,069
+95% +$6.01M ﹤0.01% 2073
2022
Q2 		$5.32M Sell
174,962
-118,767
-40% -$3.59M ﹤0.01% 2427
2022
Q1 		$8.98M Buy
293,729
+1,783
+0.6% +$53.4K ﹤0.01% 2338
2021
Q4 		$9.12M Buy
291,946
+140,749
+93% +$4.21M ﹤0.01% 2341
2021
Q3 		$2.31M Buy
151,197
+136,187
+907% +$2.37M ﹤0.01% 2814
2021
Q2 		$279K Buy
+15,010
New +$277K ﹤0.01% 3273
2019
Q3 		– Sell
-11,120
Closed -$110K – 3438
2019
Q2 		$110K Hold
11,120
– – ﹤0.01% 3389
2019
Q1 		$113K Hold
11,120
– – ﹤0.01% 3370
2018
Q4 		$70K Hold
11,120
– – ﹤0.01% 3379
2018
Q3 		$147K Hold
11,120
– – ﹤0.01% 3331
2018
Q2 		$102K Hold
11,120
– – ﹤0.01% 3301
2018
Q1 		$54K Hold
11,120
– – ﹤0.01% 3311
2017
Q4 		$31K Buy
+11,120
New +$30.2K ﹤0.01% 3313

Other funds holding XENE

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

Dimensional Fund Advisors's XENE Position: Q2 2026 in Review

Dimensional Fund Advisors opened a new position in Xenon Pharmaceuticals (XENE) in Q2 2026: 36,595 shares worth $2.21M. The stake represents ﹤0.01% of the portfolio and ranks #2723 among its holdings. This is a return to the name: Dimensional Fund Advisors previously reported a position in XENE as recently as Q4 2025.

Dimensional Fund Advisors first reported a position in XENE in Q4 2017 and has held it in 26 quarters since. The position peaked at $20.3M in Q4 2025. 315 funds tracked by Wall St. Rank hold XENE as of Q2 2026.

  • Dimensional Fund Advisors held 36,595 shares of Xenon Pharmaceuticals worth $2.21M as of Q2 2026.
  • Xenon Pharmaceuticals was a new Dimensional Fund Advisors position in Q2 2026.
  • Xenon Pharmaceuticals made up ﹤0.01% of Dimensional Fund Advisors's portfolio in Q2 2026, its #2723 holding.
  • Dimensional Fund Advisors first reported a position in Xenon Pharmaceuticals in Q4 2017 and has held it in 26 quarters since.
  • Dimensional Fund Advisors's Xenon Pharmaceuticals position peaked at $20.3M in Q4 2025.
  • 315 funds tracked by Wall St. Rank held Xenon Pharmaceuticals as of Q2 2026.

Based on Dimensional Fund Advisors's 13F filing for Q2 2026, filed 11 Aug 2026.